BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expanding Scalable AI-Powered Biomedical Insight Platform to Large Enterprises
BullFrog AI (NASDAQ: BFRG) has announced the launch of its new BullFrog Data Networks™ Solutions Library, an enterprise-scale evolution of its AI-powered biomedical insights platform. Set to launch in late 2025, the platform features native deployment support across major cloud services including Google Cloud, Microsoft Azure, and AWS.
The platform is organized into specialized solution modules for different aspects of drug discovery and development, leveraging the company's bfLEAP™ causal AI engine. The solution is specifically designed for large pharmaceutical and biotechnology organizations, offering scalable infrastructure for analyzing complex biomedical datasets.
This development positions BullFrog AI in the rapidly growing AI drug discovery market, which is projected to reach $35.4 billion by 2034 with a 29.6% CAGR.
BullFrog AI (NASDAQ: BFRG) ha annunciato il lancio della sua nuova BullFrog Data Networks™ Solutions Library, un'evoluzione su scala aziendale della sua piattaforma di analisi biomedica basata sull'intelligenza artificiale. Prevista per la fine del 2025, la piattaforma supporta nativamente il deployment sui principali servizi cloud tra cui Google Cloud, Microsoft Azure e AWS.
La piattaforma è suddivisa in moduli di soluzioni specializzate per diversi aspetti della scoperta e dello sviluppo di farmaci, sfruttando il motore di intelligenza artificiale causale bfLEAP™ dell'azienda. La soluzione è progettata appositamente per grandi aziende farmaceutiche e biotecnologiche, offrendo un'infrastruttura scalabile per l'analisi di complessi dataset biomedici.
Questo sviluppo posiziona BullFrog AI nel mercato in rapida crescita della scoperta di farmaci tramite AI, che si prevede raggiungerà un valore di 35,4 miliardi di dollari entro il 2034 con un tasso di crescita annuo composto (CAGR) del 29,6%.
BullFrog AI (NASDAQ: BFRG) ha anunciado el lanzamiento de su nueva BullFrog Data Networks™ Solutions Library, una evolución a escala empresarial de su plataforma de análisis biomédico impulsada por inteligencia artificial. Prevista para finales de 2025, la plataforma ofrece soporte nativo para su implementación en los principales servicios en la nube, incluyendo Google Cloud, Microsoft Azure y AWS.
La plataforma está organizada en módulos de soluciones especializadas para distintos aspectos del descubrimiento y desarrollo de fármacos, aprovechando el motor de IA causal bfLEAP™ de la compañía. La solución está diseñada específicamente para grandes organizaciones farmacéuticas y biotecnológicas, ofreciendo una infraestructura escalable para analizar conjuntos de datos biomédicos complejos.
Este desarrollo posiciona a BullFrog AI en el mercado de descubrimiento de fármacos con IA en rápido crecimiento, que se proyecta alcanzará los 35.400 millones de dólares para 2034 con una tasa compuesta anual de crecimiento (CAGR) del 29,6%.
BullFrog AI (NASDAQ: BFRG)는 AI 기반 생의학 인사이트 플랫폼의 기업 규모 진화 버전인 새로운 BullFrog Data Networks™ Solutions Library 출시를 발표했습니다. 2025년 말 출시 예정인 이 플랫폼은 Google Cloud, Microsoft Azure, AWS 등 주요 클라우드 서비스에 대한 네이티브 배포를 지원합니다.
이 플랫폼은 회사의 bfLEAP™ 인과 AI 엔진을 활용하여 약물 발견 및 개발의 다양한 측면을 위한 전문 솔루션 모듈로 구성되어 있습니다. 이 솔루션은 대형 제약 및 생명공학 기업을 위해 설계되었으며, 복잡한 생의학 데이터셋 분석을 위한 확장 가능한 인프라를 제공합니다.
이번 개발로 BullFrog AI는 AI 기반 약물 발견 시장에서 빠르게 성장하는 위치를 확보했으며, 이 시장은 2034년까지 354억 달러에 달할 것으로 예상되며 연평균 성장률(CAGR)은 29.6%입니다.
BullFrog AI (NASDAQ : BFRG) a annoncé le lancement de sa nouvelle BullFrog Data Networks™ Solutions Library, une évolution à l’échelle entreprise de sa plateforme d’analyse biomédicale propulsée par l’intelligence artificielle. Prévue pour fin 2025, la plateforme offre un support natif pour le déploiement sur les principaux services cloud tels que Google Cloud, Microsoft Azure et AWS.
La plateforme est organisée en modules de solutions spécialisées couvrant différents aspects de la découverte et du développement de médicaments, en s’appuyant sur le moteur d’IA causale bfLEAP™ de la société. Cette solution est spécialement conçue pour les grandes entreprises pharmaceutiques et biotechnologiques, offrant une infrastructure évolutive pour analyser des ensembles de données biomédicales complexes.
Cette avancée positionne BullFrog AI sur le marché en forte croissance de la découverte de médicaments par IA, qui devrait atteindre 35,4 milliards de dollars d’ici 2034 avec un taux de croissance annuel composé (TCAC) de 29,6%.
BullFrog AI (NASDAQ: BFRG) hat die Einführung seiner neuen BullFrog Data Networks™ Solutions Library bekannt gegeben, einer unternehmensweiten Weiterentwicklung seiner KI-gestützten biomedizinischen Analyseplattform. Die Plattform, die Ende 2025 auf den Markt kommen soll, unterstützt die native Bereitstellung über große Cloud-Dienste wie Google Cloud, Microsoft Azure und AWS.
Die Plattform ist in spezialisierte Lösungsmodule für verschiedene Aspekte der Wirkstoffforschung und -entwicklung unterteilt und nutzt die bfLEAP™ Kausal-KI-Engine des Unternehmens. Die Lösung ist speziell für große Pharma- und Biotechnologieunternehmen konzipiert und bietet skalierbare Infrastruktur zur Analyse komplexer biomedizinischer Datensätze.
Diese Entwicklung positioniert BullFrog AI im schnell wachsenden KI-Wirkstoffforschungsmarkt, der bis 2034 voraussichtlich 35,4 Milliarden US-Dollar erreichen wird und eine durchschnittliche jährliche Wachstumsrate (CAGR) von 29,6% aufweist.
- Platform supports deployment across major cloud providers (GCP, Azure, AWS) ensuring enterprise-grade scalability and security
- Modular design enables recurring revenue through long-term engagements with pharmaceutical clients
- Positioned to capture share in the growing AI drug discovery market projected to reach $35.4B by 2034
- Built on proven technology already showing success in oncology and neuropsychiatric applications
- Product launch not expected until later in 2025
- Will face competition in the rapidly growing AI drug discovery market
Insights
BullFrog AI's new enterprise solution leverages cloud infrastructure to transform large-scale drug development with potential for significant recurring revenue.
BullFrog AI's new Data Networks™ Solutions Library represents a strategic expansion of their AI-powered biomedical platform specifically targeting large pharmaceutical and biotechnology enterprises. This evolution is architecturally significant as it offers native deployment across all three major cloud platforms—Google Cloud, Microsoft Azure, and AWS—giving the company flexibility to meet clients where their data resides.
The platform's modular design, organized into specialized solution components for different drug development stages, creates a scalable business model with potential for recurring revenue through long-term enterprise engagements. By addressing the
The technical architecture leverages cloud-native elasticity while maintaining compliance with global data privacy standards—critical for handling sensitive biomedical datasets. This positions BullFrog to potentially capture high-value, multi-year contracts from major pharmaceutical companies looking to reduce R&D costs and failure rates.
While the press release doesn't provide specific revenue projections, the subscription-style model suggests improved revenue predictability compared to one-off engagements. The platform builds upon their existing bfLEAP™ causal AI engine, which has already demonstrated value in oncology and neuropsychiatric applications, providing a foundation of proven technology to support their enterprise expansion.
New Data Networks Solutions Library includes native deployment support across Google Cloud Platform, Microsoft Azure, and Amazon Web Services
Built for scale, security, and domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations
GAITHERSBURG, Md., July 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today unveiled its new BullFrog Data Networks™ Solutions Library, an enterprise-wide evolution of its proprietary data insights platform powered by the bfLEAP™ causal AI engine.
Expected to launch later in 2025, BullFrog AI’s Data Networks™ Solutions Library is designed specifically for large-scale pharmaceutical, biotechnology, and life sciences organizations that require secure, high-performance infrastructure to extract insights from vast, multi-modal biomedical datasets. Much like a well-stocked library, the platform is organized into specialized “volumes” or solution modules—each focused on a critical area of drug discovery and development, such as target selection, mechanism-of-action analysis, or clinical trial optimization. BullFrog AI can “pull a book off the shelf” to access targeted insights or combine multiple volumes to build a customized, end-to-end decision support system utilizing the client’s data lake.
Enterprise-Wide Solution Backed by the World’s Leading Cloud Platforms
With native deployment support across Google Cloud Platform (“GCP”), Microsoft Azure, and Amazon Web Services (“AWS”), the BullFrog Data Networks Solutions Library delivers best-in-class scalability, uptime, and information security. These partnerships ensure BullFrog AI can process, model, and analyze massive and sensitive biomedical datasets while maintaining full compliance with global data privacy and security standards.
“This platform positions BullFrog AI to become a trusted infrastructure partner for global pharmaceutical leaders,” commented Vin Singh, Founder and CEO of BullFrog AI. “By aligning with trusted cloud partners and delivering solutions at scale, we’re accelerating insight generation for clients who demand performance, flexibility, and compliance.”
Whether operating entirely in the cloud or across hybrid environments, BullFrog AI will meet enterprises where their data resides—enabling seamless data access, reduced integration overhead, and faster onboarding. This architecture empowers R&D teams to accelerate drug discovery and development cycles without sacrificing explainability and transparency.
By harnessing cloud-native elasticity and global reach, the BullFrog Data Networks Solutions Library enables lightning-fast deployment of the bfLEAP™ platform. Clients working with BullFrog AI can now explore novel biomarkers, optimize trial designs, and stratify patient cohorts across multiple disease areas with unprecedented speed and depth.
Purpose-Built for Enterprise-Scale Drug Development
BullFrog Data Networks™ Solutions Library builds on the success of the original BullFrog Data Networks™, which has already demonstrated value in oncology and neuropsychiatric applications. As large biopharma companies seek to reduce R&D costs and failure rates, the BullFrog Data Networks Solutions Library further strengthens BullFrog AI’s position at the forefront of AI-driven drug discovery and development—offering differentiated insights that inform every stage of the development lifecycle.
The BullFrog Data Networks Solutions Library is designed for scalable deployment and recurring revenue through long-term engagements with top-tier pharma clients by offering modular, cross-department analytics components. Each component draws from the same rigorously engineered bfLEAP™ building blocks, so value scales organically across the organization while supporting predictable, subscription-style revenue.
According to Polaris Market Research, the global AI in drug discovery market is projected to reach
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
What is BullFrog AI's (BFRG) new Solutions Library and when will it launch?
Which cloud platforms will support BullFrog AI's (BFRG) new solution?
How does BullFrog AI's (BFRG) Solutions Library generate revenue?
What is the market potential for BullFrog AI's (BFRG) drug discovery platform?
What types of organizations is BullFrog AI's (BFRG) Solutions Library designed for?
